Human EGFR Stable Cell Line - CT26

Photodynamic therapy (PDT) is a promising treatment modality that induces cell death and immune activation in tumors by generating reactive oxygen species. However, its effectiveness can be limited by the cytoprotective response of tumor cells, including increased expression of glucose-regulated protein 78 (GRP78). To overcome this challenge, the researchers explored combining PDT with EGF-SubA, a cytotoxin that targets GRP78, to enhance PDT's immunostimulatory effects. In their study, they used the CT26 mouse colon cancer cell line, which was stably transfected to express human EGFR. This enabled the researchers to evaluate the impact of EGFR overexpression on the efficacy of PDT combined with EGF-SubA. The researchers demonstrated that EGFR-expressing CT26 cells were more sensitive to EGF-SubA, which cleaves GRP78 and enhances the cytotoxicity of PDT in vitro. This study supports the potential of combining PDT with GRP78-targeting strategies in cancer treatment.

Figure 1. The researchers infected CT26 cells with retroviruses carrying human EGFR to generate CT26-EGFR cells and confirmed high EGFR expression by flow cytometry. (Gabrysiak M, et al., 2016)

Creative Biogene's Human EGFR Stable Cell Line - CT26 is an ideal model for investigating EGFR-targeted therapies. The cell line offers a robust system to study the effects of EGFR overexpression on cancer cell response to various treatments, including PDT and targeted cytotoxins like EGF-SubA.